coronavirus vaccine

Pfizer Says Trials Suggest Vaccine Works Against South African Variant

"It is an important step to further confirm the strong efficacy and good safety data we have seen so far," BioNTech CEO Ugur Sahin said

NBCUniversal Media, LLC

Pfizer and BioNTech said Thursday that trials suggest their vaccine is effective against a coronavirus variant that first emerged in South Africa, which some experts worry might evade existing shots.

The drugmakers also said in a statement that 12,000 people involved in their Phase 3 trial experienced high levels of protection against COVID-19 six months after their second dose, with no serious safety concerns, NBC News reports.

"It is an important step to further confirm the strong efficacy and good safety data we have seen so far," said Ugur Sahin, CEO and cofounder of BioNTech.

Coronavirus Pandemic

Full coverage of the COVID-19 outbreak and how it impacts you

CDC Advisers Meet Friday to Decide Fate of J&J's COVID Vaccine

CDC ‘Looking at' Revising Guidance on Masks Outdoors

"These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population."

Read the full story on NBCNews.com

Contact Us